This year, Saengyu Therapy, which simultaneously addresses glycotoxins and mucous membranes to maximize the synergy between internal organs, has gained popularity, leading to increased sales in some pharmacies.
Common conditions like dry eye syndrome, acid reflux, and gastritis all share one thing in common: they stem from issues with mucous membranes. The human body is largely composed of mucous membranes, so keeping them healthy can prevent many diseases.
Mucous membranes have a natural regeneration cycle, regularly replacing old cells with new ones. However, when glycotoxins accumulate on the mucous membranes, regeneration is inhibited, leaving the old, degraded membranes in place. Over time, these membranes deteriorate, and if this process repeats, mucous membrane diseases can develop.
Saengyu Therapy is unique because it combines mucous membrane regeneration with glycotoxin breakdown technology. Hyaluronic acid helps regenerate the mucous membranes while patented probiotics remove glycotoxins. This combination creates a powerful synergy, maximizing the function of the body’s mucous membrane organs.
MetaCen Therapeutics, the biotech company behind Saengyu Therapy, is recognized for its cutting-edge glycotoxin breakdown technology and next-generation hyaluronic acid technology. The company has attracted over 100 billion KRW in investment due to its strong technological capabilities. MetaCen Therapeutics is also conducting joint research and clinical trials with institutions such as the Korea Food Research Institute and Korea University Hospital, and is actively pursuing new drug development through domestic and international infrastructure.
Dr. Eun-Ju Jung, a pharmacist at Yoonjung Onnuri Pharmacy, who first applied the Saengyu Therapy combination, stated, "Saengyu Therapy is a groundbreaking combination, with results showing in as little as three days. MetaCen Therapeutics' technology has made a significant contribution to the operation of member pharmacies."

Source: [YaksanGongron]  (https://www.kpanews.co.kr)